Physician profile
Michell A Cadiz
NPI 1194161554
$15,897.05
in general payments reported to CMS, 2019-2025
44 companies · $4,020 in 2025
The $4,020 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $952 · 2022: $2,245 · 2023: $6,378 · 2024: $2,302 · 2025: $4,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,822 · Consulting Fee: $5,712 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,822.34 |
| Consulting Fee | $5,712.18 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,684.00 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Morphosys, US INC. | $2,154.92 | 2021-2023 | Monjuvi |
| Janssen Scientific Affairs, LLC | $1,034.42 | 2022-2025 | Talvey, Tecvayli, Darzalex |
| Celgene Corporation | $1,023.09 | 2021-2025 | Pomalyst, Reblozyl |
| Janssen Pharmaceuticals, INC | $915.00 | 2025 | |
| Sobi, INC | $863.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $674.63 | 2023-2025 | Calquence |
| Amgen INC. | $574.58 | 2021-2023 | Xgeva, Nplate, Kyprolis |
| Novartis Pharmaceuticals Corporation | $563.87 | 2022-2025 | |
| Incyte Corporation | $510.42 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Alexion Pharmaceuticals, INC. | $467.69 | 2021-2025 | Ultomiris |
| Genzyme Corporation | $389.01 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $327.70 | 2022-2025 | Ninlaro, Iclusig, Livtencity |
| Pfizer INC. | $286.09 | 2024-2025 | |
| Dova Pharmaceuticals | $258.11 | 2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $253.56 | 2021-2024 | Bavencio |
| Beigene USA, INC. | $171.57 | 2021-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $152.52 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Sanofi-Aventis U.S. LLC | $146.81 | 2022 | |
| Jazz Pharmaceuticals INC. | $137.15 | 2022-2025 | |
| Adc Therapeutics America, INC. | $117.50 | 2022-2024 | |
| Boston Scientific Corporation | $113.87 | 2023 | Accolade Sr, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Ipsen Biopharmaceuticals, INC | $97.36 | 2023-2025 | Somatuline Depot, Onivyde |
| Seagen INC. | $96.81 | 2021-2023 | Tukysa |
| Glaxosmithkline, LLC. | $96.76 | 2021-2025 | Ojjaara, Arexvy, Shingrix |
| Daiichi Sankyo INC. | $92.85 | 2021-2025 | Vanflyta |
| Secura Bio, INC. | $66.91 | 2023-2025 | Copiktra |
| Blueprint Medicines Corporation | $65.71 | 2023-2025 | Ayvakit |
| Abbvie INC. | $64.99 | 2023 | |
| Puma Biotechnology, INC. | $57.95 | 2023 | |
| Gilead Sciences, INC. | $51.92 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $49.87 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $46.08 | 2023-2025 | Keytruda, Dificid, Prevymis |
| Eisai INC. | $45.46 | 2023-2024 | |
| Epizyme, INC. | $45.00 | 2021 | |
| Astellas Pharma US INC | $31.84 | 2025 | Xospata |
| Karyopharm Therapeutics INC. | $31.49 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.20 | 2025 | Lynozyfic |
| Abbott Laboratories | $21.33 | 2025 | 2nd Gen Centrimag Primary Console |
| Alnylam Pharmaceuticals INC. | $21.24 | 2025 | Givlaari |
| Recordati_rare_diseases_inc. | $18.97 | 2023 | Sylvant |
| Stemline Therapeutics INC. | $16.93 | 2025 | Elzonris |
| Servier Pharmaceuticals LLC | $16.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michell Cadiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.